Parkinson Disease Clinical Trial
Official title:
Measurement of P-Glycoprotein Function in Alzheimer Disease, Parkinson Disease, and Frontotemporal Dementia Using Positron Emission Tomography
This study will measure the function of a protein called P-glycoprotein (P-gp), which is
found at the blood-brain barrier, a membrane that normally prevents toxic material from
entering the brain. Impaired P-gp function may allow toxins to enter the brain and cause some
people to develop certain brain diseases.
Healthy subjects and people with Alzheimer s disease, Parkinson s disease or frontotemporal
dementia who are 35 years of age or older and in overall good health may be eligible for this
study.
Participants undergo the following procedures during three outpatient visits to the NIH
Clinical Center:
- Medical history, psychological evaluation, physical examination and blood and urine
tests, including tests for illegal and addictive drugs.
- PET scan: This test uses small amounts of a radioactive chemical called a tracer that
labels active areas of the brain so the activity can be seen with a special camera.
Before starting the scan, a catheter (plastic tube) is placed in a vein in the arm to
inject the tracer. The subject lies on the scanner bed, with a special mask fitted to
the head and attached to the bed to help keep the head still during the scan so the
images obtained are clear. A brief initial scan is done to calibrate the scanner. Then,
a radioactive tracer called [(15)O]H(2)O is injected into the catheter and the PET
camera takes pictures of blood flow to the brain for about 60 seconds. Next, another
tracer, [(11)C]dLop, is injected into the catheter and pictures are taken for about 2
hours to determine how much of this tracer is allowed to enter the brain.
- Magnetic resonance imaging (MRI): This procedure is done within 1 year (before or after)
the PET scan. MRI uses a magnetic field and radio waves to produce images of the brain.
For this procedure, the patient lies on a table that can slide in and out of the scanner
(a tube-like device), wearing earplugs to muffle loud knocking and thumping sounds that
occur during the scan.
Objective
Alzheimer disease (AD), Parkinson disease (PD), and frontotemporal dementia (FTD) are
associated with the accumulation of neurotoxic material in the brain. Potentially toxic
material is normally restricted from the brain by P-glycoprotein, a transporter protein
expressed by endothelial cells at the blood-brain barrier. Disruption of the blood-brain
barrier has been reported in animal models of AD, PD, and FTD, and specific dysfunction of
P-gp has been linked to AD and PD pathology. Therefore, P-gp may be protective against
certain neurodegenerative diseases, and P-gp dysfunction may be a risk factor for developing
AD, PD, or FTD.
Positron emission tomography (PET) imaging can measure P-gp function. If P-gp function is
abnormal, a radiolabeled P-gp substrate will cross the blood-brain barrier and enter the
brain. Intact P-gp function, on the other hand, will prevent the substrate from entering the
brain. If P-gp dysfunction is a risk factor for developing AD, PD, or FTD, then patients with
these diseases should have more radiolabeled substrate in the brain than healthy controls.
We have developed a novel radioligand, [(11)C]N-desmethyl-loperamide [(11)C]dLop), which is a
P-gp substrate. Our goal is to use PET imaging with [(11)C]dLop to see if P-gp function is
reduced in AD, PD, and FTD.
Study population
In this protocol, we wish to evaluate 15 patients with AD, 15 patients with PD, 15 patients
with FTD, and 15 healthy volunteers.
Design
Subjects will undergo screening with a history, physical exam, ECG, and blood and urine
laboratory testing. Subjects will receive a dedicated brain PET with [(11)C]dLop and a brain
MRI. Since [11C]dLop uptake is influenced by blood flow, a [(15)O]H2O PET scan will be
performed to determine flow to the brain.
Outcome measures
Our outcome measure will be the amount of [(11)C]dLop uptake in the brain in AD, PD, and FTD
patients and in healthy controls. Brain uptake will be measured as the percent standardized
uptake value (%SUV). Percent SUV reflects the measured brain radioactivity after [(11)C]dLop
injection, corrected for patient weight and the injected dose of [(11)C]dLop. As an
exploratory outcome measure, we also will correct brain uptake for cerebral blood flow. Blood
flow will be determined using [(15)O]H2O PET.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05415774 -
Combined Deep Brain Stimulation in Parkinson's Disease
|
N/A | |
Recruiting |
NCT04691661 -
Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease
|
Phase 2 | |
Active, not recruiting |
NCT05754086 -
A Multidimensional Study on Articulation Deficits in Parkinsons Disease
|
||
Completed |
NCT04045925 -
Feasibility Study of the Taïso Practice in Parkinson's Disease
|
N/A | |
Recruiting |
NCT04194762 -
PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation
|
N/A | |
Completed |
NCT02705755 -
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT05830253 -
Free-living Monitoring of Parkinson's Disease Using Smart Objects
|
||
Recruiting |
NCT03272230 -
Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System
|
N/A | |
Recruiting |
NCT06139965 -
Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
|
||
Completed |
NCT04580849 -
Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease
|
N/A | |
Completed |
NCT03980418 -
Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam
|
N/A | |
Completed |
NCT04477161 -
Effect of Ketone Esters in Parkinson's Disease
|
N/A | |
Completed |
NCT04942392 -
Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic
|
N/A | |
Terminated |
NCT03446833 -
LFP Beta aDBS Feasibility Study
|
N/A | |
Completed |
NCT03497884 -
Individualized Precise Localization of rTMS on Primary Motor Area
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT04997642 -
Parkinson's Disease and Movement Disorders Clinical Database
|
||
Completed |
NCT04117737 -
A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson
|
N/A | |
Recruiting |
NCT03618901 -
Rock Steady Boxing vs. Sensory Attention Focused Exercise
|
N/A |